Analyzing Anika Therapeutics (NASDAQ:ANIK) & MediWound (NASDAQ:MDWD)

Anika Therapeutics (NASDAQ:ANIK) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, institutional ownership, risk, dividends and earnings.

Analyst Ratings

This is a summary of current recommendations for Anika Therapeutics and MediWound, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1	1	2	0	2.25
MediWound	1	0	4	0	2.60

Anika Therapeutics currently has a consensus target price of $22.00, suggesting a potential upside of 59.30%. MediWound has a consensus target price of $33.00, suggesting a potential upside of 154.43%. Given MediWound’s stronger consensus rating and higher probable upside, analysts clearly believe MediWound is more favorable than Anika Therapeutics.

Institutional and Insider Ownership

91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 12.1% of Anika Therapeutics shares are held by company insiders. Comparatively, 9.2% of MediWound shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

Anika Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, MediWound has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500.

Valuation and Earnings

This table compares Anika Therapeutics and MediWound”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$123.43 million	1.50	-$10.88 million	($0.13)	-106.23
MediWound	$11.86 million	14.22	-$23.88 million	($1.80)	-7.21

Anika Therapeutics has higher revenue and earnings than MediWound. Anika Therapeutics is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Anika Therapeutics and MediWound’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-1.43%	1.87%	1.39%
MediWound	-170.10%	-47.24%	-24.27%

Summary

Anika Therapeutics beats MediWound on 9 of the 14 factors compared between the two stocks.

About Anika Therapeutics

Anika Therapeutics is a medical technology company focused on orthopedic care and regenerative medicine. Founded in 1992 and headquartered in Bedford, Massachusetts, the company develops products using hyaluronic acid, a substance found naturally in the body and used in treatments for joint and tissue conditions. Its products include Orthovisc and Monovisc, injectable hyaluronic acid treatments for knee osteoarthritis. Anika also offers orthopedic products for areas such as sports medicine, joint preservation, and bone repair, including its Tactoset bone-void filler.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a commercial-stage biotechnology company focused on developing and marketing innovative enzymatic therapies for complex wounds. The company’s products are designed to support the removal of damaged tissue and improve wound management, with an emphasis on severe burns and hard-to-heal chronic wounds. MediWound’s lead product, NexoBrid, is a bromelain-based topical biological product used for the enzymatic removal of eschar, or dead tissue, from deep partial-thickness and full-thickness thermal burns.